N/A N=34 A Bilateral Dispensing Clinical Trial of Sapphire Lens Against Senofilcon A Lens Over 2 Weeks
Myopia · Hyperopia
Primary: Vision Quality — 93; 94 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 CP-690,550 Thorough QTc Study
Healthy
Primary: Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose — 416.48; 417.77 milliseconds (msec)
N/A N=1,145 Integrated Management Program Advancing Community Treatment of Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants With Cardiovascular Hospitalization and AF-related Emergency Department Visits — 118; 130 Participants
Phase 2 N=455 A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Osteoarthritis
Primary: Change From Baseline Osteoarthritis (OA) Pain in the Target Knee — -23.3; -23.5; -21.3; -22.1 score on a scale — p=0.575
N/A N=40 Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
Multiple Sclerosis
Primary: Expanded Disability Status Score — 2.9; 2.6 score on a scale
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
N/A N=64 Exploratory Study Of The ERCC-1 Gene
Colon Cancer · Rectal Cancer
Primary: Number of Patients With Excision Repair Cross-complementing Group-1 (ERCC1) Protein Change When Treated With Oxaliplatin — 25 Participants
N/A N=9 Spinal Cord Stimulation to Treat Hypertension
Hypertension
Primary: Change in Exercise Pressor Reflex From Baseline — 8.67; 16.29 mmHG
N/A N=101 A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer
Colectomy; Gynecological; Thoracic
Primary: Percent of Vessels Where Hemostasis (<= Grade 3) is Achieved Using ENSEAL X1 — 100.0; 94.2; 96.7; 96.2 Percentage of Vessels
Phase 2 N=200 A Study of TRV130 for the Treatment of Pain After Abdominoplasty
Pain
Primary: Time Weighted Average (TWA) Change From Baseline in Pain Score Over 24 Hours Between TRV130 and Placebo — -3.8; -1.7; -3.5; -1.2 score on a scale
Phase 2 N=87 ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Alopecia
Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
N/A N=24 Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy
Neuromuscular Diseases
Primary: Change in Antibiotic Courses — 4; 1; 2.50; 1.00 Courses of antibiotics — p=<0.001
N/A N=268 Clinical Study of Approved Contact Lenses
Myopia
Primary: End of Day Comfort — 80; 80 score on a scale
Phase 4 N=100 RCT Superior Hypogastric Block During LH
Hysterectomy
Primary: Postoperative Pain Scores — 3.9; 4.7 score on a scale